Designing and interpreting limiting dilution assays: General principles and applications to the latent reservoir for human immunodeficiency virus-1

Open Forum Infectious Diseases

Volumn 2, Issue 4, 2015, Pages

  Rosenbloom, Daniel I S ^a   Elliott, Oliver ^a   Hill, Alison L ^b   Henrich, Timothy J ^c   Siliciano, Janet M ^d   Siliciano, Robert F ^d,e  

^a NewYork Presbyterian Hospital   (United States)

^b HARVARD UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Dilution assay; HIV; Latent reservoir; Maximum likelihood statistics; Viral outgrowth

Indexed keywords

ASSAY; CD4 LYMPHOCYTE COUNT; DISEASE CARRIER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LATENT VIRUS INFECTION; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIMITING DILUTION ASSAY; MAXIMUM LIKELIHOOD METHOD; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; VIRUS LATENCY; VIRUS REPLICATION;

EID: 85014373238     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofv123     Document Type: Review

References (35)

1. Finzi D, HermankovaM, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-300.
2. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727-8.
3. Ho Y-C, Shan L, Hosmane NN, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013; 155:540-51.
4. Eriksson S, Graf EH, Dahl V, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013; 9: e1003174.
5. Cohn LB, Silva IT, Oliveira TY, et al. HIV-1 integration landscape during latent and active infection. Cell 2015; 160:420-32.
6. Myers LE, McQuay LJ, Hollinger FB. Dilution assay statistics. J Clin Microbiol 1994; 32:732-9.
7. Fisher RA. On the mathematical foundations of theoretical statistics. Phil Trans R Soc A 1922; 222:309-68.
8. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-8.
9. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487:482-5.
10. Henrich TJ, Hu Z, Li JZ, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013; 207:1694-702.
11. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013; 369:1828-35.
12. Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 2013; 9:e1003347.
13. Bullen CK, Laird GM, Durand CM, et al. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 2014; 20:425-9.
14. Luzuriaga K, Gay H, Ziemniak C, et al. Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med 2015; 372:786-8.
15. Laird GM, Eisele EE, Rabi SA, et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog 2013; 9: e1003398.
16. Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol 2014; 14:24-35.
17. de St Groth F. The evaluation of limiting dilution assays. J Immunol Methods 1982; 49:R11-23.
18. Mehrabi Y, Matthews JN. Implementable Bayesian designs for limiting dilution assays. Biometrics 1998; 54:1398-406.
19. Siliciano JD, Siliciano RF. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol 2005; 304:3-15.
20. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009; 347:70-8.
21. Buzón MJ, Sun H, Li C, et al. HIV-1 persistence in CD4(+) T cells with stem cell-like properties. Nat Med 2014; 20:139-42.
22. Hill AL, Rosenbloom DIS, Fu F, et al. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci U S A 2014; 111:13475-80.
23. Chomont N. A novel assay that precisely measures the size of the latent HIV reservoir reveals that ART-naïve individuals harbour a large pool of latently infected CD4+ T cells. In: IAS Towards a Cure Symposium; 2014; Melbourne, Australia.
24. Pasternak AO, Jurriaans S, Bakker M, et al. Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One 2009; 4:e8490.
25. Pasternak AO, Adema KW, Bakker M, et al. Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol 2008; 46:2206-11.
26. Lassen KG, Ramyar KX, Bailey JR, et al. Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog 2006; 2:e68.
27. Chakraborty AK, Das J. Pairing computation with experimentation: a powerful coupling for understanding T cell signalling. Nat Rev Immunol 2010; 10:59-71.
28. Weinberger LS, Burnett JC, Toettcher JE, et al. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 2005; 122:169-82.
29. Singh A, Weinberger LS. Stochastic gene expression as a molecular switch for viral latency. Curr Opin Microbiol 2009; 12:460-6.
30. Rouzine IM, Razooky BS, Weinberger LS. Stochastic variability in HIV affects viral eradication. Proc Natl Acad Sci U S A 2014; 111:13251-52.
31. Laird GM, Bullen CK, Rosenbloom DIS, et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 2015; 125:1901-12.
32. Schwerdt CE, Fogh J. The ratio of physical particles per infectious unit observed for poliomyelitis viruses. Virology 1957; 4:41-52.
33. Parker RF. Statistical studies of the nature of the infectious unit of vaccine virus. J Exp Med 1938; 67:725-38.
34. Besnier C, Takeuchi Y, Towers G. Restriction of lentivirus in monkeys. Proc Natl Acad Sci U S A 2002; 99:11920-25.
35. Debaisieux S, Rayne F, Yezid H, Beaumelle B. The ins and outs of HIV-1 Tat. Traffic 2012; 13:355-63.